Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
July 2026 – November 2026 · 3 captures · latest observed messagingBest-in-class technology. Tissue-free detection.
Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. With a single, scalable platform, Adela can address the unmet need br
16 July 2026 · Best-in-class technology. Tissue-free detection.archived page
12 October 2026 · Best-in-class technology. Tissue-free detection.archived page
4 November 2026 · Best-in-class technology. Tissue-free detection.current websiteHistorical capture not publicly available
January 2022 – April 2026 · 8 capturesA breakthrough approach to cancer detection
Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests. With a single, scalable platform, Adela can address the unmet need br